{
    "root": "302d101f-f454-b60a-e063-6294a90a9743",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "MIFEPREX",
    "value": "20250312",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MIFEPRISTONE",
            "code": "320T6RNW1F"
        }
    ],
    "indications": "MIFEPREX is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.",
    "contraindications": "200 mg MIFEPREX on Day 1, followed 24-48 hours after MIFEPREX dosing by 800 mcg buccal misoprostol. ( 2.1 ) Instruct the patient what to do if significant adverse reactions occur. ( 2.2 ) Follow-up is needed to confirm complete termination of pregnancy. ( 2.3 )",
    "warningsAndPrecautions": "is only available through a restricted program called the Mifepristone REMS Program\n \n  [see Warnings and Precautions (\n  \n   5.3)].\n \n  \n                  \n                  MIFEPREX is supplied as light yellow, cylindrical, and bi-convex tablets imprinted on one side with “MF.” Each tablet contains 200 mg of mifepristone. One tablet is individually blistered on one blister card that is packaged in an individual package (National Drug Code 64875-001-01).\n                  Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Administration of MIFEPREX and misoprostol for the termination of pregnancy (the “treatment procedure”) is contraindicated in patients with any of the following conditions:\n  \n   \n                           Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy)\n    \n     [see Warnings and Precautions (\n     \n      5.4)]\n    \n     \n                           \n                           Chronic adrenal failure (risk of acute adrenal insufficiency)\n                           Concurrent long-term corticosteroid therapy (risk of acute adrenal insufficiency)\n                           History of allergy to mifepristone, misoprostol, or other prostaglandins (allergic reactions including anaphylaxis, angioedema, rash, hives, and itching have been reported\n    \n     [see Adverse Reactions (\n     \n      6.2)]\n    \n     )\n   \n    \n                           Hemorrhagic disorders or concurrent anticoagulant therapy (risk of heavy bleeding)\n                           Inherited porphyrias (risk of worsening or of precipitation of attacks)\n                        \n                     \n                     Use of MIFEPREX and misoprostol for termination of intrauterine pregnancy is contraindicated in patients with an intrauterine device (“IUD”) in place (the IUD might interfere with pregnancy termination). If the IUD is removed, MIFEPREX may be used."
}